that is probrably in reference to re analysis of the phase 3 data or the sterilization of the syringes issues - but it isnt in reference to the need for 2 bioavailablity tests/trials or the QT study.
It's goign to be atleast middle of next year before this one gets another shot at approval. For the record 5 months before the PDUFA in Oct 2009 - the stock was .80 - I expect it to trade well below that level as it has less cash - and longer to go for approval now. I am basing my .40 area target based on expected dillution of atleast 20m shares - and having an 18 month time horizon rather then a 6 month horizon.
I think it's got 50% more to fall (doesnt have to happen all today) - good luck to everyone. Don't fall the the cheerleading or the hype here. Use logic. If this was .80 in Oct with 5 months to the PDUFA - why would it now be worth MORE with less cash and 3x as long to wait?
News 
Market Data 
Discover 
AI
